title: Outcomes of regenerative treatment with rhPDGF-BB and rhFGF-2 for periodontal intra-bony defects: a systematic review and meta-analysis.
abstract: BACKGROUND
  The aim was to evaluate the effects of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) and recombinant human fibroblast growth factor-2 (rhFGF-2) on treating periodontal intra-bony defects, compared to the control (carrier alone).
  
  
  METHODS
  Electronic and hand searches were performed to identify eligible studies. The weighed mean differences of linear defect fill (LDF), probing depth (PD) reduction, clinical attachment level (CAL) gain and gingival recession (GR) were calculated using random effect meta-analysis.
  
  
  RESULTS
  The searches yielded 1018 articles, of which seven studies were included. Only one included study was considered at low risk of bias. The outcomes that reached statistical significance in comparison to carriers alone included: LDF (0.95 mm, 95% CI: 0.62-1.28 mm or 20.17%, 95% CI: 11.81-28.54%) and CAL gain (0.34 mm, 95% CI: 0.03-0.65 mm) for PDGF, and LDF (21.22%, 95% CI: 5.82-36.61%) for FGF-2.
  
  
  CONCLUSIONS
  Within the limits of this review, rhPDGF-BB demonstrated significantly more LDF and CAL gain; rhFGF-2 resulted in significantly higher percentage of LDF.
authors.affiliation: Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI, USA; Currently Advanced Periodontology Program, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.
authors.forename: Vahid
authors.initials: V
authors.lastname: Khoshkam
authors.forename: Hsun-Liang
authors.initials: HL
authors.lastname: Chan
authors.forename: Guo-Hao
authors.initials: GH
authors.lastname: Lin
authors.forename: James
authors.initials: J
authors.lastname: Mailoa
authors.forename: William V
authors.initials: WV
authors.lastname: Giannobile
authors.forename: Hom-Lay
authors.initials: HL
authors.lastname: Wang
authors.forename: Tae-Ju
authors.initials: TJ
authors.lastname: Oh
mesh_terms: D016301:Alveolar Bone Loss / Q000601:surgery*; D000077214:Becaplermin; D001861:Bone Regeneration / Q000187:drug effects; D016222:Fibroblast Growth Factor 2 / Q000627:therapeutic use*; D005889:Gingival Recession / Q000601:surgery; D016557:Guided Tissue Regeneration, Periodontal / Q000379:methods*; D006801:Humans; D017622:Periodontal Attachment Loss / Q000601:surgery; D010514:Periodontal Pocket / Q000601:surgery; D020574:Proto-Oncogene Proteins c-sis / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D020574:Proto-Oncogene Proteins c-sis; D016222:Fibroblast Growth Factor 2; D000077214:Becaplermin
keywords: bioengineering; oral reconstruction and wound healing; regenerative medicine; repair; tissue engineering